Low-temperature cold-prepared high-activity skin microcirculation promoting composition and preparation method thereof

By combining low-temperature cold and high-activity compositions to promote skin microcirculation, using ingredients such as caffeine and ultra-high-speed high-pressure microjet homogenization technology, the problems of weak effects of existing eye products and high-temperature processes have been solved, and significant eye problems have been achieved. Improve results and sustainable production.

CN118948663AInactive Publication Date: 2024-11-15宁波伯通伟达生物医药有限公司

Patent Information

Application Number
CN202411031431.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing eye skin care products are weak in desalinating dark circles and eliminating edema. The use of caffeine and other ingredients may irritate the eyes. The high-temperature stirring process affects the activity of components, and the production consumes high energy, making it difficult to achieve sustainability.

Method used

Low temperature cold combination with high activity to promote skin microcirculation composition, including caffeine, diosamine, eccrine saponin, forskolin and other components, through hydroxypropyl-β-cyclodextrin and hydroxypropyl-γ- Cyclodextrin wrapping treatment, and ultra-high-speed high-pressure microjet homogenization technology is used to form supramolecular structures, realize the cold distribution process of the composition, reduce biotoxicity, and improve permeability and bioavailability.

Benefits of technology

It significantly improves the microcirculation of the eye, quickly eliminates edema and dark circles, reduces eye bags, reduces production energy consumption, simplifies process flow, and achieves sustainable and environmentally friendly production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948663A_ABST
    Figure CN118948663A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of cosmetics, and particularly relates to a low-temperature cold-prepared high-activity skin microcirculation promoting composition and a preparation method thereof. The low-temperature cold-matched high-activity composition for promoting skin microcirculation is prepared from hydroxypropyl-beta-cyclodextrin, hydroxypropyl-gamma-cyclodextrin, caffeine, diosmin, escin, carnosine, 3-O-ethyl ascorbic acid ether and the like. The low-temperature cold-prepared high-activity skin microcirculation promoting composition is prepared from different causes of edema, under-eye puffiness and dark eye circles, so that the eye problem is solved in a multi-target manner, and the effect of eliminating cell and microvessel edema is achieved; meanwhile, skin microcirculation can be promoted, and eye edema caused by unsmooth microcirculation is improved; finally, excess fat accumulation of the eyes also increases the volume of the eye pouch, and the eriochin increases the adenosine cyclophosphate level by activating adenylate cyclase to realize activation of hormone-sensitive lipase and start degradation of fat.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of cosmetics, and in particular relates to a low-temperature cold-formulated high-activity composition for promoting skin microcirculation and a preparation method thereof. Background Art

[0002] As we age, human skin shows signs of aging. Initially, the basal layer and spinous layer in the epidermis become disordered, the junction between the epidermis and dermis becomes flat, and the thickness of the epidermis decreases. Then, fibroblasts in the dermis secrete elastic fibers. Collagen fibers decrease until the skin loses elasticity and wrinkles form. This process is irreversible, so the skin needs to be treated step by step and according to the characteristics of each part of the skin for early anti-aging intervention.

[0003] The eye skin is the weakest part of the facial skin. The average thickness of the skin is only 1 / 4 of that of other areas. The connective tissue is loose, and the content of collagen and elastin in the dermis is low and easily lost. The facial muscles contract frequently due to blinking every day, which causes wrinkles. In addition, the density of nerve fibers and capillaries is high. Most modern people have the habit of staying up late, which can easily lead to poor blood circulation and accumulation of exudate in the subcutaneous tissue layer. In summary, there are three major problems around the eyes: (i) wrinkles; (ii) dark circles; and (iii) eye bags.

[0004] More specific:

[0005] (i) As for wrinkles, eye wrinkles are divided into static wrinkles and dynamic wrinkles according to their causes. Static wrinkles are caused by the loss of collagen and elastin in the dermis. Usually, collagen is supplemented and the DEJ layer is thickened to reduce wrinkles. In the past two years, the trend has been to supplement recombinant human collagen to achieve the effect of reducing static wrinkles. The generation of dynamic wrinkles is due to the combination of neurotransmitters (acetylcholine) released from the pre-protrusion membrane and receptors on the post-protrusion membrane, which causes intercellular information transmission, excitation of the post-protrusion membrane, and mediates muscle contraction. Usually, peptides such as arginine can significantly reduce the generation of dynamic wrinkles. In skin care, the problem of eye wrinkles has been well solved.

[0006] (ii) As for dark circles, there are usually three types of dark circles: pigmentary dark circles, vascular dark circles and structural dark circles. The dark circles we often talk about are vascular dark circles, which are mainly caused by staying up late and overusing the eyes, resulting in a decrease in the oxygen content of red blood cell hemoglobin in the blood vessels around the eyes, a large amount of deoxyhemoglobin accumulates, and the blood vessels appear bluish purple. This is common in young people and is caused by poor microcirculation, which is relatively difficult to improve.

[0007] (iii) As for eye bags, the most common type of eye bags is temporary eye bags, also known as eyelid edema. Due to lack of sleep, excessive use of eyes, kidney disease, pregnancy, irregular menstruation, etc., the blood and lymphatic circulation function is reduced, resulting in congestion of lymphatic vessels and increased permeability of capillaries, increased blood osmotic pressure, decreased tissue fluid osmotic pressure, resulting in fluid accumulation, and the problem of eye bags is still difficult to solve.

[0008] Therefore, based on this, the technical solution of the present invention is proposed. Summary of the invention

[0009] In order to solve the problems existing in the prior art, the present invention provides a low-temperature cold-formulated high-activity composition for promoting skin microcirculation, comprising phase A, phase B, phase C, phase D and phase E; wherein:

[0010] The phase A comprises the following raw materials in parts by weight: 10 to 20 parts of hydroxypropyl-β-cyclodextrin, 1 to 5 parts of hydroxypropyl-γ-cyclodextrin and 15 to 30 parts of water;

[0011] The phase B comprises the following raw materials in parts by weight: 5-20 parts of caffeine, 0.1-5 parts of diosmin, 0.1-5 parts of aescin, and 0.1-5 parts of forskolin;

[0012] The phase C comprises the following raw materials in parts by weight: 0.5-2 parts of carnosine, 1-5 parts of 3-O-ethyl ascorbic acid ether, and 15-30 parts of water;

[0013] The phase D comprises the following raw materials in parts by weight: 0.5-5 parts of polyglycerol-6 pentaoleate, 0.5-5 parts of sesame seed oil, and 0.5-5 parts of succinic acid;

[0014] The phase E comprises the following raw materials in parts by weight: 0.1 to 3 parts of pentylene glycol and 0.1 to 3 parts of ethylhexylglycerin.

[0015] Preferably, in the low-temperature cold-formulated high-activity composition for promoting skin microcirculation, the phase A comprises the following raw materials in parts by weight: 15 parts of hydroxypropyl-β-cyclodextrin, 3 parts of hydroxypropyl-γ-cyclodextrin and 20 parts of water;

[0016] The phase B comprises the following raw materials in parts by weight: 12 parts of caffeine, 2.5 parts of diosmin, 2.5 parts of aescin, and 2.5 parts of forskolin;

[0017] The phase C comprises the following raw materials in parts by weight: 1 part of carnosine, 3 parts of 3-O-ethyl ascorbic acid ether, and 22 parts of water;

[0018] The phase D comprises the following raw materials in parts by weight: 2.5 parts of polyglycerol-6 pentaoleate, 2.5 parts of sesame seed oil, and 2.5 parts of succinic acid;

[0019] The phase E comprises the following raw materials in parts by weight: 1.5 parts of pentylene glycol and 1.5 parts of ethylhexylglycerin.

[0020] Based on the same technical concept, another solution of the present invention is to provide a method for preparing a low-temperature cold-formulated high-activity composition for promoting skin microcirculation, the preparation method comprising the following steps:

[0021] (1) dissolving hydroxypropyl-β-cyclodextrin and hydroxypropyl-γ-cyclodextrin in phase A in water, heating and stirring to obtain liquid A;

[0022] (2) adding phase B into the liquid A and stirring to obtain a mixed liquid AB;

[0023] (3) adding the pre-dissolved phase C, phase D and phase E to the mixed liquid AB, and stirring evenly to obtain a total mixed liquid;

[0024] (4) Injecting the total mixed solution into an ultra-high-speed high-pressure microfluidizer for circulation operation to obtain the low-temperature cold-formulated high-activity composition for promoting skin microcirculation.

[0025] Preferably, in step (1), hydroxypropyl-β-cyclodextrin and hydroxypropyl-γ-cyclodextrin in phase A are dissolved in water, the temperature is raised to 45-55° C., and stirred at 50-60 r / min for 0.5-1 h to obtain liquid A.

[0026] Preferably, in step (2), phase B is added to the liquid A, and stirred at a speed of 30 to 35 r / min at room temperature to obtain a mixed liquid AB.

[0027] Preferably, in step (3), the pre-dissolved phase C, phase D and phase E are added to the mixed liquid AB, and the mixture is homogenized at 45 to 50 r / min for 10 to 15 minutes to obtain a total mixed liquid.

[0028] Preferably, in step (4), the total mixed solution is injected into a high-pressure microfluidizer for 2 to 3 cycles to obtain the low-temperature cold-formulated high-activity composition for promoting skin microcirculation.

[0029] Preferably, the pressure of the high-pressure microfluidizer is set to 20,000-30,000 psi, the homogenization time is 0.5-3 hours, and the operating temperature is 20-30°C.

[0030] The beneficial effects of the present invention are:

[0031] 1. The present invention aims at the problems that the eye products such as eye cream and eye mask on the market have unclear mechanisms for reducing dark circles and eliminating edema, weak effects, and strong stimulation (most of the eye products on the market only use peptides and caffeine to solve eye problems such as crow's feet and reducing dark circles, but the disadvantage is that the efficacy is weak, and the direct use of caffeine will stimulate the eyelids and cause eye irritation risks), and provides a low-temperature cold-mixed high-activity composition for promoting skin microcirculation. It is mainly composed of caffeine, diosmin, aescin, forskolin, carnosine, and 3-O-ethyl ascorbic acid ether. The composition is assembled from different causes of edema and eye bags, and multiple targets are used to solve eye problems. Caffeine is a xanthine alkaloid, similar to adenosine, and can bind to adenosine receptor A1 to increase the level of neurotransmitter acetylcholine (ACh), thereby mediating a sharp increase in the dilation of skin cells and microvasculature, thereby accelerating water circulation and achieving the effect of eliminating cell and microvascular edema. In addition, transcutaneous oxygen partial pressure also affects microcirculation. Aescin activates the decomposition of heme and reduces transcutaneous oxygen partial pressure PO2, which can promote skin microcirculation and improve eye edema caused by poor microcirculation. In addition, lymphatic return will also aggravate edema. Diosmin increases the speed of lymphatic drainage and shrinks lymphatic vessels, speeds up the return of interstitial fluid, improves lymphatic return, and reduces edema. Finally, excess fat accumulation in the eyes will also increase the size of eye bags, and forskolin activates adenylate cyclase to increase the level of cyclic adenosine monophosphate to activate hormone-sensitive lipase and start fat degradation.

[0032] 2. Since microcirculation raw materials such as caffeine, diosmin, and aescin are insoluble in water and only slightly soluble in hot water, the present invention uses hydroxypropyl-β-cyclodextrin and hydroxypropyl-γ-cyclodextrin to encapsulate them, and then uses ultra-high-speed high-pressure microfluidization homogenization technology to form a supramolecular structure. Compared with untreated caffeine, its biological toxicity directly acting on the skin is reduced, and a progressive dynamic release mechanism is established at the same time, which can significantly improve the permeability, realize the cold preparation process of the composition, and maintain the activity of the composition to the greatest extent. Compared with the ordinary encapsulated caffeine (lipoid) on the market, the particle size is smaller, and the supramolecular biological structure further improves the permeability, improves the bioavailability and activity.

[0033] 3. Since caffeine, diosmin, aescin, etc. are insoluble or non-water-soluble raw materials with very low solubility, a high-temperature stirring and dissolving process must be used in the existing process. However, such operation is not only easy to affect the activity of other components, but also extremely time-consuming and labor-intensive. Compared with high-temperature emulsification, the cold emulsification process adopted in the present invention can greatly reduce production energy consumption, reduce carbon dioxide emissions, and achieve sustainability and environmental friendliness. At the same time, the production process is simplified, long links such as heating and cooling are omitted, and production capacity is improved.

[0034] 4. The preparation method is easy to operate, does not require complicated equipment, and is green and environmentally friendly. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0036] Figure 1 It is a data chart of permeability and permeability rate of different groups.

[0037] Figure 2 This is a picture of the capillaries on the eyelids before using the product.

[0038] Figure 3 This is a picture of the capillaries on the eyelids after using the product. DETAILED DESCRIPTION

[0039] To make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described in detail below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other implementation methods obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.

[0040] Example 1

[0041] This embodiment provides a method for preparing a low-temperature cold-formulated high-activity composition for promoting skin microcirculation, characterized in that the preparation method comprises the following steps:

[0042] (1) Dissolve 10 g of hydroxypropyl-β-cyclodextrin and 1 g of hydroxypropyl-γ-cyclodextrin in phase A in 20 g of water, heat to 45° C., and stir at 50 r / min for 0.5 h to obtain liquid A;

[0043] (2) adding phase B (5 g caffeine, 0.1 g diosmin, 0.1 g aescin, and 0.1 g forskolin) to the liquid A, stirring at a speed of 30 r / min at room temperature to obtain a mixed liquid AB;

[0044] (3) adding the pre-dissolved phase C (0.5 g carnosine, 1 g 3-O-ethyl ascorbic acid ether and 15 g water), phase D (0.5 g polyglycerol-6 pentaoleate, 0.5 g sesame seed oil, 0.5 g succinic acid) and phase E (0.1 g pentanediol, 0.1 g ethylhexylglycerol) to the mixed liquid AB, and stirring and homogenizing at 45 r / min for 10 min to obtain a total mixed liquid;

[0045] (4) Injecting the total mixed solution into a high-pressure microfluidizer for circulation operation twice to obtain the low-temperature cold-formulated high-activity composition for promoting skin microcirculation; the pressure of the high-pressure microfluidizer is set to 20,000 psi, the homogenization time is 3 hours, and the operating temperature is 30°C.

[0046] Example 2

[0047] This embodiment provides a method for preparing a low-temperature cold-formulated high-activity composition for promoting skin microcirculation, characterized in that the preparation method comprises the following steps:

[0048] (1) Dissolve 20 g of hydroxypropyl-β-cyclodextrin and 5 g of hydroxypropyl-γ-cyclodextrin in phase A in 30 g of water, heat to 55° C., and stir at 60 r / min for 1 h to obtain liquid A;

[0049] (2) adding phase B (30 g caffeine, 5 g diosmin, 5 g aescin, and 5 g forskolin) to the liquid A, stirring at a speed of 35 r / min at room temperature to obtain a mixed liquid AB;

[0050] (3) adding the pre-dissolved phase C (2 g carnosine, 5 g 3-O-ethyl ascorbic acid ether and 30 g water), phase D (5 g polyglycerol-6 pentaoleate, 5 g sesame seed oil, 5 g succinic acid) and phase E (3 g pentanediol, 3 g ethylhexylglycerol) to the mixed liquid AB, and stirring and homogenizing at 50 r / min for 15 min to obtain a total mixed liquid;

[0051] (4) Injecting the total mixed solution into a high-pressure microfluidizer and performing a circulation operation for 3 times to obtain the low-temperature cold-formulated high-activity composition for promoting skin microcirculation; the pressure of the high-pressure microfluidizer is set to 30,000 psi, the homogenization time is 0.5 h, and the operating temperature is 20°C.

[0052] Example 3

[0053] This embodiment provides a method for preparing a low-temperature cold-formulated high-activity composition for promoting skin microcirculation, characterized in that the preparation method comprises the following steps:

[0054] (1) Dissolve 15 g of hydroxypropyl-β-cyclodextrin and 3 g of hydroxypropyl-γ-cyclodextrin in phase A in 20 g of water, heat to 50° C., and stir at 65 r / min for 1 h to obtain liquid A;

[0055] (2) adding phase B (17 g caffeine, 2.5 g diosmin, 2.5 g aescin, and 2.5 g forskolin) to the liquid A, stirring at a speed of 35 r / min at room temperature to obtain a mixed liquid AB;

[0056] (3) adding the pre-dissolved phase C (1 g carnosine, 3 g 3-O-ethyl ascorbic acid ether and 22 g water), phase D (2.5 g polyglycerol-6 pentaoleate, 2.5 g sesame seed oil, 2.5 g succinic acid) and phase E (1.5 g pentanediol, 1.5 g ethylhexylglycerol) to the mixed liquid AB, and stirring and homogenizing at 50 r / min for 12 min to obtain a total mixed liquid;

[0057] (4) Injecting the total mixed solution into a high-pressure microfluidizer for circulatory operation three times to obtain the low-temperature cold-formulated high-activity composition for promoting skin microcirculation; the pressure of the high-pressure microfluidizer is set to 25000 psi, the homogenization time is 1.5 h, and the operating temperature is 25°C.

[0058] Verification Example

[0059] (I) Particle size test

[0060] 1. Purpose of the experiment

[0061] In this test, a particle size analyzer was used to determine the particle size distribution of the material before and after high-pressure microfluidization homogenization.

[0062] 2. Test equipment and materials

[0063] 2.1 Equipment

[0064] Anton paar Litesizer 500 Particle Size Analyzer

[0065] 2.2 Test subjects

[0066] The low-temperature cold-formulated high-activity composition for promoting skin microcirculation obtained in Example 3 (after high-pressure microjet homogenization, test group) and the total mixed solution obtained in Example 3 (before high-pressure microjet homogenization, control group).

[0067] 2.3 Experimental steps

[0068] 2.3.1 Sample processing

[0069] The sample is diluted in a particle size bottle according to the product quality standard. The sample solution in the particle size bottle should be ultrasonicated for 1 minute before being put on the machine. During the ultrasonication process, the pipette is used to continuously suck and spit to ensure the uniformity of the sample solution. After the ultrasonication is completed, about 1mL of sample solution (about 1 / 3) is sucked and added to the measuring cell for testing.

[0070] 2.3.2 Measurement samples

[0071] Follow the instrument instructions, open the sample cell cover, put in the measuring cell, set the pressure to 25000psi, and click Start to start the measurement.

[0072] 2.3.2 Results Analysis

[0073] When the measurement is completed, the result is automatically generated.

[0074] 3. Test results

[0075] The test results show that compared with the control group, the particle size of the test group after high-pressure microfluidization homogenization is significantly smaller, from the volume average particle size D(4,3)=6.890μm to D(4,3)=0.582μm. In addition, compared with D10 and D50, the D90 of the test group is significantly smaller than that of the control group, indicating that the particle size distribution is more uniform and stable, and there is no nano-liquid particle agglomeration phenomenon. The results are shown in Table 1.

[0076] Table 1 Particle size distribution

[0077]

[0078]

[0079] (II) Permeability test

[0080] 1. Test purpose and principle

[0081] This study used Franz diffusion cells to investigate the percutaneous penetration of caffeine in test samples and blank control samples under simulated physiological conditions. Piglet skin was fixed between the receiving pool and the supply pool, with the stratum corneum in contact with the test substance and the lower layer of the skin in contact with the receiving solution. The caffeine content in the receiving solution and the amount of caffeine retained in the skin at different time periods were tested to investigate the ability of the test samples to promote caffeine penetration.

[0082] 2. Test equipment and materials

[0083] 2.1 Equipment

[0084] TK-12D drug transdermal diffusion tester, Fanz cell, high performance liquid chromatograph, ultrasonic cleaner, analytical balance.

[0085] 2.2 Reagents and consumables

[0086] Phosphate buffer, anhydrous ethanol, methanol, azone, caffeine. Excised skin of Bama Xiang pigs aged 30 days.

[0087] 2.3 Sample information

[0088] Test group: the low-temperature cold-formulated high-activity composition for promoting skin microcirculation obtained in Example 3.

[0089] Blank group: the total mixed solution obtained in Example 3 (sample not homogenized by high-pressure microfluidization)

[0090] Comparison group: Commercially available products with caffeine content similar to that of the test group (Caffeine Herbasome manufacturer: lipod)

[0091] 3. Test methods

[0092] 3.1 Skin treatment

[0093] The ex vivo skin of Bama Xiang pig stored at -18°C was thawed with physiological saline at room temperature, cut into original sheets with a diameter of about 20 mm using a skin cutter, and then repeatedly rinsed with phosphate buffer.

[0094] 3.2 Experimental procedures

[0095] (1) The skin was fixed in a Franz diffusion cell with the stratum corneum facing the donor chamber.

[0096] (2) Add the test substance to the skin surface of the donor chamber and spread it evenly. The effective contact area is about 1.7 cm 2 , three parallel tests were set up for each group of samples.

[0097] (3) Add receiving solution into the receiving chamber, make the receiving solution closely contact the skin and remove air bubbles.

[0098] (4) Infiltration conditions: magnetic stirrer speed 250 pm, water bath temperature 32°C, and supply chamber located above the waterline.

[0099] (5) Samples of the receiving chamber solution were taken at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, and 6 h to test the caffeine content. At each time point, all the receiving solution in the receiving tank was removed and replaced to provide the best solubility sink conditions.

[0100] (6) After 6 hours, use a pipette to draw 1.5 mL of phosphate buffer solution to wash the skin surface several times. Take out the liquid and place it in a 10 mL volumetric flask. Repeat the washing for 5 times. Combine the phosphate buffer solution and make up to 10 mL for measurement.

[0101] (7) Residue in the skin: After 6 h, the ex vivo skin fixed in the Franz diffusion cell was removed and cut into pieces. 10 mL of ethanol phosphate buffer was added and ultrasonically extracted for 30 min. The extraction was repeated twice, and the combined extracts were adjusted to 25 mL for testing.

[0102] 4. Test results

[0103] The results are shown in Table 2 and Figure 1 shown.

[0104] Table 2 Caffeine penetration

[0105]

[0106]

[0107] From Table 2 and Figure 1The results show that the blank group, test group and control group were subjected to quantitative permeation analysis. Compared with the blank group and control group that were not homogenized by high-pressure microfluidization, the permeation speed and amount of caffeine in the test group were greatly improved, with the permeation rate reaching a maximum of 8.5 μg / min at 3 hours and the permeation rate reaching a maximum of 79.8% at 6 hours.

[0108] (III) Blood circulation promotion test

[0109] 1. Test principle and purpose

[0110] By observing the capillaries in the wrinkles of the lower eyelid, the changes in microcirculation before and after the use of the product can be verified.

[0111] The skin's microcirculation is a complex power system that plays a very important role in skin color, temperature regulation, skin metabolism, and transdermal transport. The color (red) of a certain part of the skin depends on the blood flow in this area. There is an indirect and non-constant relationship between skin blood flow and skin color. Products that promote skin microcirculation can delay skin aging. The mechanism is that the blood flow rate is accelerated, providing sufficient oxygen and nutrients to the skin's keratinocytes, etc., and timely removing the cell's metabolic products and various harmful substances (such as superoxide anions, etc.), reducing the oxidation of collagen fibers, so that the various cells of the skin maintain good functions, the stratum corneum is well hydrated, and the skin surface is bright and shiny. At the same time, the microcirculation speed is accelerated, the number of red blood cells passing through the skin per unit time increases, the amount of hemoglobin increases, and the red component of the skin increases, and the skin color is rosy.

[0112] 2. Experimental instruments

[0113] ANYTY 3R-MSBTVTY ANYTY USB high-speed autofocus microscope

[0114] 3. Test steps

[0115] 3.1 Before applying, use X-CRYSTAL to test the blood flow of the test subject's lower eyelid

[0116] 3.2 The tester evenly applied the low-temperature cold-formulated high-activity composition for promoting skin microcirculation obtained in Example 3 to the lower eyelid, and retested the blood flow after the liquid was completely absorbed after 5 minutes.

[0117] 4. Test blood flow velocity

[0118] 5. Test results are as follows Figure 2 and Figure 3 As shown, the results show that the capillary blood flow velocity of the lower eyelid after use of the product is significantly greater than before use, and more capillary blood flux is activated. This shows that Example 3 can promote eye microcirculation and accelerate the elimination of edema and dark circles.

[0119] (IV) Average blood perfusion analysis

[0120] 1. Purpose of the test

[0121] The average blood perfusion PU value of the skin is measured by a blood flow irrigation meter, which can reflect the blood perfusion status of the skin and quantitatively measure the changes in the microcirculation of the skin before and after long-term use of the product through data.

[0122] 2. Experimental instruments

[0123] PeriCam PSISystem Laser Blood Flow Irrigation Tester

[0124] 3. Test steps

[0125] 3.1 Measurement and modeling before the formal experiment (D-1): After 30 minutes of facial cleansing, use PeriCam PSI System to take facial photos, determine the target analysis position, and use analysis software to obtain the average skin blood perfusion PU value, and the measured value is used as the initial value (D-1). Then tell the subjects to stay up until 4 a.m. that night.

[0126] 3.2 Measurement (D0 / D1 / D7 / D14): During the follow-up visit on the second day (D0), the subjects need to undergo the same index test, and the measured value is used as the baseline value (D0), and then the product (Example 3) is distributed and the method of use is instructed. The subjects need to be followed up 1 day, 7 days and 14 days (D1, D7 and D14) after using the product and undergo the same index test.

[0127] The test of the same subject should be completed by the same instrument and the same tester. The test site should be kept consistent between the two test time points.

[0128] 4. Results Analysis

[0129] The results are shown in Tables 3 and 4. The average blood perfusion after staying up late increased significantly compared with the initial value before staying up late (D-1), indicating that the modeling was successful. After using the product, the average blood perfusion gradually decreased to no significant difference from before staying up late, indicating that it was gradually recovering to the state before staying up late.

[0130] Average blood perfusion change rate = (average blood perfusion after using the product - average blood perfusion before using the product) / average blood perfusion before using the product × 100%

[0131] Table 3 Descriptive statistics of mean blood perfusion PU value (n=32)

[0132] Group Number of people average value Standard Deviation Standard error Minimum Maximum median D-1 32 137.66 18.55 3.35 95.7 189.52 132.08 D0 32 150.06 31.19 5.58 94.14 216.68 142.03 D1 32 143.17 20.55 3.7 94.37 203.14 140.4 D7 32 140.75 20.03 3.61 101.9 181.56 134.7 D14 32 139.6 16.9 3.06 94.56 198.65 139.24

[0133] Table 4 Analysis of differences in mean blood perfusion PU values ​​(x±s, n-32)

[0134]

[0135]

[0136] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A low-temperature cold-formulated high-activity composition for promoting skin microcirculation, characterized in that: Including phase A, phase B, phase C, phase D and phase E; among which: The phase A comprises the following raw materials in parts by weight: 10 to 20 parts of hydroxypropyl-β-cyclodextrin, 1 to 5 parts of hydroxypropyl-γ-cyclodextrin and 15 to 30 parts of water; The phase B comprises the following raw materials in parts by weight: 5-20 parts of caffeine, 0.1-5 parts of diosmin, 0.1-5 parts of aescin, and 0.1-5 parts of forskolin; The phase C comprises the following raw materials in parts by weight: 0.5-2 parts of carnosine, 1-5 parts of 3-O-ethyl ascorbic acid ether, and 15-30 parts of water; The phase D comprises the following raw materials in parts by weight: 0.5-5 parts of polyglycerol-6 pentaoleate, 0.5-5 parts of sesame seed oil, and 0.5-5 parts of succinic acid; The phase E comprises the following raw materials in parts by weight: 0.1 to 3 parts of pentylene glycol and 0.1 to 3 parts of ethylhexylglycerin.

2. The low-temperature cold-formulated high-activity composition for promoting skin microcirculation according to claim 1, characterized in that: The phase A comprises the following raw materials in parts by weight: 15 parts of hydroxypropyl-β-cyclodextrin, 3 parts of hydroxypropyl-γ-cyclodextrin and 20 parts of water; The phase B comprises the following raw materials in parts by weight: 12 parts of caffeine, 2.5 parts of diosmin, 2.5 parts of aescin, and 2.5 parts of forskolin; The phase C comprises the following raw materials in parts by weight: 1 part of carnosine, 3 parts of 3-O-ethyl ascorbic acid ether, and 22 parts of water; The phase D comprises the following raw materials in parts by weight: 2.5 parts of polyglycerol-6 pentaoleate, 2.5 parts of sesame seed oil, and 2.5 parts of succinic acid; The phase E comprises the following raw materials in parts by weight: 1.5 parts of pentylene glycol and 1.5 parts of ethylhexylglycerin.

3. The method for preparing the low-temperature cold-formulated high-activity composition for promoting skin microcirculation according to claim 1 or 2, characterized in that: The preparation method comprises the following steps: (1) dissolving hydroxypropyl-β-cyclodextrin and hydroxypropyl-γ-cyclodextrin in phase A in water, heating and stirring to obtain liquid A; (2) adding phase B into the liquid A and stirring to obtain a mixed liquid AB; (3) adding the pre-dissolved phase C, phase D and phase E to the mixed liquid AB, and stirring evenly to obtain a total mixed liquid; (4) injecting the total mixed solution into an ultra-high-speed high-pressure microfluidizer for circulation operation to obtain the low-temperature cold-formulated high-activity composition for promoting skin microcirculation.

4. The method for preparing the low-temperature cold-formulated high-activity composition for promoting skin microcirculation according to claim 3, characterized in that: In step (1), hydroxypropyl-β-cyclodextrin and hydroxypropyl-γ-cyclodextrin in phase A are dissolved in water, the temperature is raised to 45-55° C., and stirred at 50-60 r / min for 0.5-1 h to obtain liquid A.

5. The method for preparing the low-temperature cold-formulated high-activity composition for promoting skin microcirculation according to claim 3, characterized in that: In step (2), phase B is added to the liquid A, and stirred at a speed of 30 to 35 r / min at room temperature to obtain a mixed liquid AB.

6. The method for preparing the low-temperature cold-formulated high-activity composition for promoting skin microcirculation according to claim 3, characterized in that: In step (3), the pre-dissolved phase C, phase D and phase E are added to the mixed liquid AB, and the mixture is homogenized at 45 to 50 r / min for 10 to 15 minutes to obtain a total mixed liquid.

7. The method for preparing the low-temperature cold-formulated high-activity composition for promoting skin microcirculation according to claim 3, characterized in that: In step (4), the total mixed solution is injected into a high-pressure microfluidizer for 2 to 3 cycles to obtain the low-temperature cold-formulated high-activity composition for promoting skin microcirculation.

8. The method for preparing the low-temperature cold-formulated high-activity composition for promoting skin microcirculation according to claim 7, characterized in that: The pressure of the high-pressure microfluidizer is set to 20,000-30,000 psi, the homogenization time is 0.5-3 hours, and the operating temperature is 20-30°C.

Citation Information

Patent Citations

  • Anti-aging eye cream for preventing and treating fat granules and preparation method thereof

    CN112006930A

  • Composition and application thereof in preparation of product with function of resisting eye aging

    CN118384063A

Cited By

  • A cosmetic composition for relieving skin swelling comprising plant-derived natural compounds and plant extracts as active ingredients

    KR103002409B1

  • A hydrogel composition for relieving skin swelling comprising plant-derived natural compounds and plant extracts as active ingredients

    KR103002414B1